Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on Zogenix (NASDAQ: ZGNX) today and set a price target of $69. The company’s shares opened today at $46.65.
According to TipRanks.com, Samimy is a 4-star analyst with an average return of 10.1% and a 52.0% success rate. Samimy covers the Healthcare sector, focusing on stocks such as Supernus Pharmaceuticals, Jazz Pharmaceuticals, and Perrigo Company plc.
Currently, the analyst consensus on Zogenix is a Moderate Buy with an average price target of $69, which is a 47.9% upside from current levels. In a report issued on August 9, Mizuho Securities also maintained a Buy rating on the stock with a $69 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $62.75 and a one-year low of $11.25. Currently, Zogenix has an average volume of 747.9K.
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is neutral on the stock. Most recently, in May 2018, Cam Garner, a Director at ZGNX sold 218 shares for a total of $8,698.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zogenix, Inc. is a pharmaceutical compan. It engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include ZX008 and Relday.
Read More on ZGNX:
